Biosite will undertake initial antibody generation on Medarex platform related to OGeS targets.

Oxford Genome Sciences (OGeS) gained access to Medarex’ fully human antibody technology and also signed on Biosite for initial research.

Biosite will carry out the early-stage antibody generation for OGeS on this transgenic mouse platform against cancer targets. OGeS will identify these targets using its OGAP® database.

OGeS will retain the worldwide license to the antibodies generated, and Medarex has the right to receive various fees and royalties. Biosite will receive access to the OGeS diagnostic targets in colorectal and ovarian cancer.

Under a separate agreement between OGeS and Biosite, Biosite may also establish a companion diagnostic assay on certain programs selected by companies.

Previous articleCHDI to Leverage ActiveSight’s Fragment-Based Lead Discovery Know-How for Huntington’s
Next articleNovasep to Take Over PharmaChem